Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial

References

• Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355(9209), 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol.23(15), 3502–3508 (2005).
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet370(9582), 135–142 (2007).
   PubMed Web of Science ®Google Scholar
• Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet370(9582), 143–152 (2007).
   PubMed Web of Science ®Google Scholar
• Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br. J. Cancer95(2), 131–138 (2006).
   PubMedGoogle Scholar
• Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer94(6), 798–805 (2006).
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol.25(13), 1670–1676 (2007).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized Phase II study. 43rd Annual Meeting of the American Society of Clinical Oncology. IL, USA, 1–5 June 2007.
   Google Scholar
• Van Cutsem E, Nowacki M, Lang I et al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. 43rd Annual Meeting of the American Society of Clinical Oncology. IL, USA, 1–5 June 2007.
   Google Scholar
• Diaz Rubio E, Tabernero J, Van Cutsem E. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international Phase II study. Proc. Am. Soc. Clin. Oncol.23, 254s (2005) (Abstract 3535).
   PubMed Web of Science ®Google Scholar
• Venook A, Niedzwiecki D, Hollis D. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX){±} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol.24, 148s (2006) (Abstract 3509).
   Google Scholar
• Cassidy JC, Diaz-Rubio SE, Scheithauer W et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer (MCRC). (2008).
   Google Scholar
• Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J. Clin. Oncol.25(Pt 1)18S 4013 (2007).
   Google Scholar
• Maughan TS, James RD, Kerr DJ et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet359(9317), 1555–1563 (2002).
   PubMed Web of Science ®Google Scholar
• Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet361(9356), 457–464 (2003).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol.24(3), 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Buyse M, Abrahantes JC et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J. Clin. Oncol.25(22), 3224–3229 (2007).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Lledo G, Delord J et al.. Modified (m)FOLFOX7/bevacizumab (B) or modified (m)XELOX/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). 43rd Annual Meeting of the American Society of Clinical Oncology. IL, USA, 1–5 June 2007.
   Google Scholar
• Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol.22(11), 2084–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol.26(12), 2006–2012 (2008).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Maughan TS; on behalf of the COIN trial Management Group and Investigators. Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. 43rd Annual Meeting of the American Society of Clinical Oncology. IL, USA, 1–5 June 2007.
   Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann J et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Presented at: 44th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May–3 June 2008.
   Google Scholar